Skip to main content
TipRanks
Go Ultimate75% OFF

BriaCell Therapeutics (BCTX) AI Stock Analysis

336 Followers
BCTX

BriaCell Therapeutics

(NASDAQ:BCTX)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Very Low LeverageThe absence of meaningful debt reduces solvency and refinancing pressure while preserving financial flexibility for research and clinical development. Compared with highly levered peers, BriaCell has fewer fixed financial obligations competing with cash needed to advance its oncology programs.
Negative Factors
Pre-Revenue BusinessWith no commercial revenue, BriaCell lacks an internally generated financial base to fund research, trials, and operating costs. Its ability to create durable value therefore remains dependent on successful development and eventual regulatory approval of its clinical-stage programs.

BriaCell Therapeutics (BCTX) vs. SPDR S&P 500 ETF (SPY)

-80%-60%-40%-20%0%20%40%BCTX-68.29%SPY+4.27%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$38.42M
Dividend Yield
―
Average Volume (3M)
250.76K
Price to Earnings (P/E)
-0.3
Beta (1Y)
1.31
Revenue Growth
―
EPS Growth
87.83%
Country
US
Employees
31
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

BriaCell Therapeutics Business Overview & Revenue Model

Company Description

BriaCell Therapeutics Corp. is a biotechnology company focused on immuno-oncology, dedicated to developing innovative immune-based therapies for cancer treatment. Its primary therapeutic candidate, Bria-IMT, is a whole-cell cancer vaccine currently u...

BriaCell Therapeutics Risk Analysis

BriaCell Therapeutics disclosed 50 risk factors in its most recent earnings report. BriaCell Therapeutics reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

BriaCell Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

BCTX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TSE:MBXTSE:MBX52NeutralCAD 40.41M-7.79-18.83%―-27.13%-1752.63%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TSE:DOSETSE:DOSE39UnderperformCAD 12.40M-4.0442.51%―-19.31%34.45%
TSE:RVXTSE:RVX39UnderperformCAD 25.82M-1.6211.24%――-28.45%

* Healthcare Sector Average

Performance Comparison

-50%-25%0%25%BCTXTSE:DOSETSE:MBXTSE:RVXTSE:GSDTSE:TTIDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
BCTX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
BCTXBriaCell Therapeutics3.06-5.44-64.00%
TSE:DOSERapid Dose Therapeutics Corp0.10-0.08-44.12%
TSE:MBXMicrobix Biosystms0.280.0414.58%
TSE:RVXResverlogix Corp.0.07-0.04-31.82%
TSE:GSDDevonian Health Group, Inc.6.75-8.25-55.00%
TSE:TTIThiogenesis Therapeutics Corp0.60-0.05-7.69%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.